A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
about
Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted TherapyRetinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cellsThe evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy.Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia.Combination strategies in myelodysplastic syndromes.The Synergistic Effects of Decitabine Combined with Arsenic Trioxide (ATO) in the Human Myelodysplastic Syndrome Cell Line SKM-1.Arsenic trioxide and triptolide synergistically induce apoptosis in the SKM‑1 human myelodysplastic syndrome cell line.CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count.A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma.Arsenic trioxide targets MTHFD1 and SUMO-dependent nuclear de novo thymidylate biosynthesis.Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.Drug Repurposing for the Treatment of Acute Myeloid Leukemia.Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.
P2860
Q26749870-EFE7A24C-2455-4951-8B0F-893A187A1164Q28393380-D14B63AF-9231-486E-82A3-B572F75A4970Q37296118-C02F445D-CCF2-4179-A274-1B72BB3D0E8DQ37910260-5BF7F5A1-7E9B-41FC-8AB1-0A6E7AFDEAECQ37973280-1C997E73-BB89-40A6-9A98-1A3432E05D56Q38733061-14366616-A4C5-4625-BEEB-92B91603A225Q38737783-94C4681C-BC8D-45E6-8DD1-6D4B92F3B6E0Q41264299-83F504FF-823B-4DFE-A8B5-93CA9CC2B656Q41385777-2FB6F014-D2A6-419F-BFEE-7EBBB8D1C08DQ41710207-83CADB65-EE7F-4B23-B697-D32538B27249Q42705834-26FE692C-0551-4954-A9A7-74810A7F0A7EQ47094576-65B43715-8209-40A3-A3EB-70C40C5C53A5Q49244147-390D3238-A990-42D1-BF8E-5520C205C122
P2860
A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
A Phase 2 study of combination ...... ondary acute myeloid leukemia.
@ast
A Phase 2 study of combination ...... ondary acute myeloid leukemia.
@en
type
label
A Phase 2 study of combination ...... ondary acute myeloid leukemia.
@ast
A Phase 2 study of combination ...... ondary acute myeloid leukemia.
@en
prefLabel
A Phase 2 study of combination ...... ondary acute myeloid leukemia.
@ast
A Phase 2 study of combination ...... ondary acute myeloid leukemia.
@en
P2093
P2860
P356
P1433
P1476
A Phase 2 study of combination ...... ondary acute myeloid leukemia.
@en
P2093
Anjali Advani
Harry P Erba
Jaroslaw P Maciejewski
Josephine Chan
Manuel Afable
Matt E Kalaycio
Mikkael A Sekeres
Ricki Englehaupt
Ronald Sobecks
Sherry Seel
P2860
P304
P356
10.1002/CNCR.25686
P407
P577
2010-10-19T00:00:00Z